Authors: Ryan, DP Supko, JG Eder, JP Seiden, MV Demetri, G Lynch, TJ Fischman, AJ Davis, J Jimeno, J Clark, JW

Citation: Dp. Ryan et al., Phase I and pharmacokinetic study of esteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies, CLIN CANC R, 7(2), 2001, pp. 231-242

Authors: Villalona-Calero, MA Eder, JP Toppmeyer, DL Allen, LF Fram, R Velagapudi, R Myers, M Amato, A Kagen-Hallet, K Razvillas, B Kufe, DW Von Hoff, DD Rowinsky, EK

Citation: Ma. Villalona-calero et al., Phase I and pharmacokinetic study of LU79553, a DNA intercalating bisnaphthalimide, in patients with solid malignancies, J CL ONCOL, 19(3), 2001, pp. 857-869

Authors: Bunnell, CA Supko, JG Eder, JP Clark, JW Lynch, TJ Kufe, DW Shulman, LN

Citation: Ca. Bunnell et al., Phase I clinical trial of 7-cyanoquinocarcinol (DX-52-1) in adult patientswith refractory solid malignancies, CANC CHEMOT, 48(5), 2001, pp. 347-355

Authors: Eder, JP Kantoff, PW Roper, K Xu, GX Bubley, GJ Boyden, J Gritz, L Mazzara, G Oh, WK Arlen, P Tsang, KY Panicali, D Schlom, J Kufe, DW

Citation: Jp. Eder et al., A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer, CLIN CANC R, 6(5), 2000, pp. 1632-1638

Authors: Supko, JG Lynch, TJ Clark, JW Fram, R Allen, LF Velagapudi, R Kufe, DW Eder, JP

Citation: Jg. Supko et al., A phase I clinical and pharmacokinetic study of the dolastatin analogue cemadotin administered as a 5-day continuous intravenous infusion, CANC CHEMOT, 46(4), 2000, pp. 319-328